ILLUSTRATE Trial: Difference between revisions
Jump to navigation
Jump to search
Rim Halaby (talk | contribs) (Created page with "__NOTOC__ {{High density lipoprotein}} {{CMG}} ==Overview== * Clinical research on torcetrapib stopped because of increased incidence of cardiovascular events as an adver...") |
Rim Halaby (talk | contribs) No edit summary |
||
| Line 13: | Line 13: | ||
[[Category:Lipopedia]] | [[Category:Lipopedia]] | ||
[[Category:HDL]] | [[Category:HDL]] | ||
[[Category:Clinical trials]] | |||
Revision as of 23:34, 17 September 2013
|
High Density Lipoprotein Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Clinical Trials |
|
Case Studies |
|
ILLUSTRATE Trial On the Web |
|
American Roentgen Ray Society Images of ILLUSTRATE Trial |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
- Clinical research on torcetrapib stopped because of increased incidence of cardiovascular events as an adverse effect of the drug.[1]
- Torcetrapib side-effects include a significant increase in systolic blood pressure (hypertension) and a significant reduction in serum potassium (hypokalemia) levels.
References
- ↑ Barter PJ, Caulfield M, Eriksson M; et al. (2007). "Effects of torcetrapib in patients at high risk for coronary events". The New England Journal of Medicine. 357 (21): 2109–22. doi:10.1056/NEJMoa0706628. PMID 17984165. Unknown parameter
|month=ignored (help)